Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Progress in Molecular Biology and Translational Science|June 12, 2016
Epigenetics of ObesityA Lopomo, E Burgio, L MiglioreThe Journal of Pharmacology and Experimental Therapeutics|December 24, 1998
Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distributionD E Burgio, M P Gosland, McNamara aPJBiochemical Pharmacology|April 12, 1996
Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysisD E Burgio, M P Gosland, P J McNamaraJournal of Pharmacological and Toxicological Methods|May 1, 1992
Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysisR A Yokel, D D Allen, D E Burgio, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 20, 2012
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 yearsM R McClung, A Balske, D E Burgio, et al.Current Medical Research and Opinion|November 1, 2007
Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot studyArtur J Racewicz, Pamela J Schofield, David L Cahall, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 19, 2005
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trialsPaul D Miller, Christian Roux, Steven Boonen, et al.Neuroscience Letters|January 6, 1999
Inhibition of brain choline uptake by isoarecolone and lobeline derivatives: implications for potential vector-mediated brain drug deliveryT L Metting, D E Burgio, A V Terry, et al.Clinical Therapeutics|March 24, 2009
Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging studyLouis-Georges Ste-Marie, Jacques P Brown, John F Beary, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 4, 2012
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year dataM R McClung, J R Zanchetta, A Racewicz, et al.Pageof 2